MedTrace Logo

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

NCT02685046 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-10-14

No results posted yet for this study

Summary

In this proof-of-concept trial the investigators will study the effects of imatinib treatment on the biology of mesenchymal-type colon cancers.

Conditions

  • Colonic Neoplasms

Interventions

DRUG

Imatinib

Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.

Sponsors & Collaborators

  • Meander Medical Center

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Hubrecht Institute

    collaborator UNKNOWN

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • I HM Borel Rinkes, MD, PhD · UMC Utrecht

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-09-01
Completion
2019-09-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685046 on ClinicalTrials.gov